SEC Filing Summary: Corcept Therapeutics Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Corcept Therapeutics Incorporated on October 6, 2025. The report discloses a change in corporate governance regarding the Board of Directors.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to a specific compensatory arrangement:
- Consulting Fee: $5,708.33 per month for the departing director.
- Equity Vesting: Previously awarded stock options will continue to vest according to the original schedule.
Material Changes
Board Departure: Gillian Cannon, Ph.D., resigned from the Board of Directors, effective October 10, 2025. The resignation is not due to any disagreement with the Company regarding operations, financial statements, or policies.
Post-Resignation Role: Dr. Cannon will transition to a consultant role providing services to the Board until the 2026 meeting of stockholders.
Outlook, Risks, and Management Commentary
Management expressed gratitude for Dr. Cannon's years of service and contributions. The filing does not contain forward-looking guidance, risk factors, or discussion of unusual items beyond the executive departure.
Key Facts for Investor Verification
- Confirm the effective date of Dr. Cannon's resignation (October 10, 2025).
- Verify the duration of the consulting agreement (through the 2026 stockholder meeting).
- Review the total value of outstanding stock options held by Dr. Cannon to assess potential dilution or expense impact.
- Check for any subsequent filings regarding the appointment of a replacement director.